4.7 Article

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

出版社

BMC
DOI: 10.1186/s13046-021-02153-9

关键词

Pancreatic cancer; Splicing-spliceosome; Pladienolide-B; cancer stem cells

类别

资金

  1. Spanish Ministry of Economy [MINECO] [BFU2016-80360-R]
  2. Ministry of Science and Innovation [MICINN] [PID2019-105201RB-I00, PID2019-105564RB-I00]
  3. European Union (ERDF/ESF, Investing in your future) [PI17/02287, PI20/01301, PI18/00757]
  4. DTS Grant [DTS20/00050]
  5. Postdoctoral Grant Sara Borrell [CD19/00255]
  6. Fundacion Asociacion Espanola Contra el Cancer (AECC) [GC16173694BARB]
  7. Spanish Ministry of Universities [FPU14/04290, FPU16/06190, FPU18/02275]
  8. Boehringer Ingelheim Fonds travel grant
  9. Junta de Andalucia [BIO0139]
  10. CIBERobn
  11. Associazione Italiana Ricerca Cancro (AIRC 5 x 1000) [12182]
  12. Fondazione Italiana Malattie Pancreas -Ministero Salute [FIMPCUP_J38D19000690001]
  13. Fondazione Cariverona: Oncology Biobank Project Antonio Schiavi [203885/2017]
  14. GETNE2016 Research grant
  15. GETNE2019 Research grant
  16. [FI17/00282]

向作者/读者索取更多资源

SF3B1 is overexpressed in human PDAC and associated with tumor grade and lymph-node involvement. Pladienolide-B targets both cancer cells and CSCs by increasing apoptosis and decreasing tumor-related features, reducing stemness capacity and increasing sensitivity to chemotherapy.
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive therapeutic target. The core splicing factor SF3B1 is heavily altered in cancer and can be inhibited by Pladienolide-B, but its actionability in PDAC is unknown. We explored the presence and role of SF3B1 in PDAC and interrogated its potential as an actionable target. Methods SF3B1 was analyzed in PDAC tissues, an RNA-seq dataset, and publicly available databases, examining associations with splicing alterations and key features/genes. Functional assays in PDAC cell lines and PDX-derived CSCs served to test Pladienolide-B treatment effects in vitro, and in vivo in zebrafish and mice. Results SF3B1 was overexpressed in human PDAC and associated with tumor grade and lymph-node involvement. SF3B1 levels closely associated with distinct splicing event profiles and expression of key PDAC players (KRAS, TP53). In PDAC cells, Pladienolide-B increased apoptosis and decreased multiple tumor-related features, including cell proliferation, migration, and colony/sphere formation, altering AKT and JNK signaling, and favoring proapoptotic splicing variants (BCL-XS/BCL-XL, KRASa/KRAS, Delta 133TP53/TP53). Importantly, Pladienolide-B similarly impaired CSCs, reducing their stemness capacity and increasing their sensitivity to chemotherapy. Pladienolide-B also reduced PDAC/CSCs xenograft tumor growth in vivo in zebrafish and in mice. Conclusion SF3B1 overexpression represents a therapeutic vulnerability in PDAC, as altered splicing can be targeted with Pladienolide-B both in cancer cells and CSCs, paving the way for novel therapies for this lethal cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据